CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade BioLife Solutions, Inc. - BLFS CFD

    Market is not available at the moment

    Market information is presented
    as of 2023-09-21

    • Summary
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    BioLife Solutions Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 14.63
    Open* 14.33
    1-Year Change* -1.31%
    Day's Range* 14.33 - 14.67
    52 wk Range 10.48-26.96
    Average Volume (10 days) 554.24K
    Average Volume (3 months) 9.01M
    Market Cap 565.37M
    P/E Ratio -100.00K
    Shares Outstanding 43.49M
    Revenue 162.22M
    EPS -1.96
    Dividend (Yield %) N/A
    Beta 1.64
    Next Earnings Date Nov 7, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    Date Close Change Change (%) Open High Low
    Jun 29, 2022 14.53 0.15 1.04% 14.38 14.69 14.23
    Jun 28, 2022 14.63 -0.35 -2.34% 14.98 15.46 14.42
    Jun 27, 2022 14.88 -0.81 -5.16% 15.69 15.75 14.38
    Jun 24, 2022 15.68 0.08 0.51% 15.60 16.45 15.49
    Jun 23, 2022 15.67 1.26 8.74% 14.41 15.72 14.41
    Jun 22, 2022 14.45 1.06 7.92% 13.39 14.81 13.39
    Jun 21, 2022 13.80 -0.14 -1.00% 13.94 14.63 13.76
    Jun 17, 2022 13.74 0.39 2.92% 13.35 14.30 13.24
    Jun 16, 2022 13.24 -0.11 -0.82% 13.35 13.66 13.07
    Jun 15, 2022 14.08 1.10 8.47% 12.98 14.23 12.97
    Jun 14, 2022 12.95 -0.17 -1.30% 13.12 13.19 12.57
    Jun 13, 2022 13.07 -0.17 -1.28% 13.24 13.66 13.01
    Jun 10, 2022 14.07 0.13 0.93% 13.94 14.24 13.78
    Jun 9, 2022 14.37 0.39 2.79% 13.98 14.52 13.98
    Jun 8, 2022 14.45 -0.03 -0.21% 14.48 15.15 14.30
    Jun 7, 2022 14.69 1.21 8.98% 13.48 14.72 13.48
    Jun 6, 2022 13.90 0.17 1.24% 13.73 14.40 13.57
    Jun 3, 2022 13.73 -0.24 -1.72% 13.97 14.02 13.48
    Jun 2, 2022 14.14 1.01 7.69% 13.13 14.36 13.13
    Jun 1, 2022 13.32 -0.44 -3.20% 13.76 14.16 13.32

    BioLife Solutions, Inc. Events

    Time (UTC) Country Event
    Tuesday, November 7, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 BioLife Solutions Inc Earnings Release
    Q3 2023 BioLife Solutions Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 161.759 119.156 48.087 27.371 19.742
    Revenue 161.759 119.156 48.087 27.371 19.742
    Cost of Revenue, Total 107.937 82.108 20.646 8.76 6.217
    Gross Profit 53.822 37.048 27.441 18.611 13.525
    Total Operating Expense 307.3 147.865 54.328 17.483 16.08
    Selling/General/Admin. Expenses, Total 69.24 47.674 21.686 13.594 8.565
    Research & Development 14.798 11.821 6.72 3.168 1.298
    Operating Income -145.541 -28.709 -6.241 9.888 3.662
    Interest Income (Expense), Net Non-Operating 0.01 -0.485 1.359 -0.238 -0.396
    Gain (Loss) on Sale of Assets
    Other, Net 0.704 0.168 3.601 -12.848 -28.271
    Net Income Before Taxes -144.827 -29.026 -1.281 -3.198 -25.005
    Net Income After Taxes -139.805 -8.908 1.983 -1.657 -25.005
    Minority Interest
    Net Income Before Extra. Items -139.805 -8.908 1.983 -1.657 -25.005
    Net Income -139.805 -8.908 1.983 -1.657 -25.005
    Income Available to Common Excl. Extra. Items -139.805 -8.908 1.822 -1.657 -25.344
    Income Available to Common Incl. Extra. Items -139.805 -8.908 1.822 -1.657 -25.344
    Diluted Net Income -139.805 -8.908 1.822 -1.657 -25.344
    Diluted Weighted Average Shares 42.481 38.5039 27.3063 19.4603 16.2565
    Diluted EPS Excluding Extraordinary Items -3.291 -0.23135 0.06672 -0.08515 -1.55901
    Diluted Normalized EPS -1.5916 -0.31508 0.08696 -0.39137 -1.55901
    Total Adjustments to Net Income 0 0 -0.161 0 -0.339
    Depreciation / Amortization 9.697 8.202 3.033 1.079 0
    Unusual Expense (Income) 110.382 -4.815 0.668 -9.168 0
    Other Operating Expenses, Total -4.754 2.875 1.575 0.05 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 39.508 37.703 44.259 40.747 40.533
    Revenue 39.508 37.703 44.259 40.747 40.533
    Cost of Revenue, Total 27.696 23.664 30.288 27.009 26.194
    Gross Profit 11.812 14.039 13.971 13.738 14.339
    Total Operating Expense 49.673 51.308 94.5 52.152 117.096
    Selling/General/Admin. Expenses, Total 21.72 21.313 19.529 16.858 17.067
    Research & Development 4.84 4.152 4.164 3.425 3.428
    Depreciation / Amortization 1.45 1.459 1.461 2.513 2.863
    Unusual Expense (Income) -5.115 0 40.464 0.001 69.905
    Other Operating Expenses, Total -0.918 0.72 -1.406 2.346 -2.361
    Operating Income -10.165 -13.605 -50.241 -11.405 -76.563
    Interest Income (Expense), Net Non-Operating -0.419 -0.411 -0.506 0.707 -0.032
    Other, Net 0.39 0.394 0.434 0.142 -0.022
    Net Income Before Taxes -10.194 -13.622 -50.313 -10.556 -76.617
    Net Income After Taxes -10.199 -13.714 -50.228 -9.957 -72.878
    Net Income Before Extra. Items -10.199 -13.714 -50.228 -9.957 -72.878
    Net Income -10.199 -13.714 -50.228 -9.957 -72.878
    Income Available to Common Excl. Extra. Items -10.199 -13.714 -50.228 -9.957 -72.878
    Income Available to Common Incl. Extra. Items -10.199 -13.714 -50.228 -9.957 -72.878
    Diluted Net Income -10.199 -13.714 -50.228 -9.957 -72.878
    Diluted Weighted Average Shares 43.4412 43.0276 42.7949 42.648 42.4602
    Diluted EPS Excluding Extraordinary Items -0.23478 -0.31873 -1.17369 -0.23347 -1.71638
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.31131 -0.31873 -0.55909 -0.23345 -0.64625
    Total Adjustments to Net Income 0 0
    Dilution Adjustment
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 138.452 126.088 114.712 24.113 37.564
    Cash and Short Term Investments 19.442 69.86 90.403 6.448 30.657
    Cash & Equivalents 19.442 69.86 90.403 6.448 30.657
    Short Term Investments
    Total Receivables, Net 33.936 23.217 8.006 5.345 3.045
    Accounts Receivable - Trade, Net 33.936 23.217 8.006 5.345 3.045
    Total Inventory 34.904 28.345 11.602 10.972 3.509
    Prepaid Expenses 6.879 4.656 4.648 1.348 0.353
    Total Assets 450.229 554.286 234.829 92.816 45.467
    Property/Plant/Equipment, Total - Net 48.266 46.611 24.517 10.534 1.319
    Property/Plant/Equipment, Total - Gross 62.389 55.624 28.77 13.229 3.647
    Accumulated Depreciation, Total -14.123 -9.013 -4.253 -2.695 -2.328
    Intangibles, Net 32.088 152.149 31.049 21.982 0
    Long Term Investments 5.069 4.372 5.872 2.5 6.548
    Other Long Term Assets, Total 1.613 0.325 0.23 0.05 0.036
    Total Current Liabilities 44.582 42.7 15.573 7.669 1.939
    Accounts Payable 15.367 14.945 3.672 3.119 0.72
    Accrued Expenses 16.245 11.405 4.931 4.173 1.089
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 10.998 15.339 6.348 0.377 0.13
    Total Liabilities 86.041 76.239 29.583 49.362 30.835
    Total Long Term Debt 23.919 6.644 0.667 0 0
    Long Term Debt 23.793 6.353 0.655
    Minority Interest
    Other Liabilities, Total 17.29 21.408 13.343 41.693 28.896
    Total Equity 364.188 478.047 205.246 43.454 14.632
    Common Stock 0.043 0.042 0.033 0.021 0.019
    Additional Paid-In Capital 611.739 585.397 302.598 143.485 113.008
    Retained Earnings (Accumulated Deficit) -246.915 -107.11 -97.385 -100.052 -98.395
    Other Equity, Total -0.679 -0.282
    Total Liabilities & Shareholders’ Equity 450.229 554.286 234.829 92.816 45.467
    Total Common Shares Outstanding 42.8322 41.8175 33.0392 20.8255 18.5474
    Redeemable Preferred Stock 0 0 0
    Total Preferred Shares Outstanding 0 0 0 0 0
    Goodwill, Net 224.741 224.741 58.449 33.637 0
    Other Current Assets, Total 43.291 0.01 0.053
    Current Port. of LT Debt/Capital Leases 1.972 1.011 0.622
    Capital Lease Obligations 0.126 0.291 0.012
    Deferred Income Tax 0.25 5.487
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 132.789 138.452 135.874 118.057 118.701
    Cash and Short Term Investments 19.105 19.442 27.036 24.001 59.463
    Cash & Equivalents 19.105 19.442 27.036 24.001 59.463
    Total Receivables, Net 30.343 33.936 32.436 31.257 24.271
    Accounts Receivable - Trade, Net 30.343 33.936 32.436 31.257 24.271
    Total Inventory 41.329 34.904 33.747 33.335 30.2
    Prepaid Expenses 6.201 6.879 8.041 6.89 4.757
    Other Current Assets, Total 35.811 43.291 34.614 22.574 0.01
    Total Assets 446.47 450.229 487.679 470.379 544.012
    Property/Plant/Equipment, Total - Net 50.939 48.266 47.236 45.873 46.647
    Property/Plant/Equipment, Total - Gross 66.013 62.389 60.495 57.457 56.851
    Accumulated Depreciation, Total -15.074 -14.123 -13.259 -11.584 -10.204
    Goodwill, Net 224.741 224.741 224.741 224.741 224.741
    Intangibles, Net 30.629 32.088 74.013 76.524 149.286
    Long Term Investments 5.069 5.069 5.069 4.372 4.372
    Other Long Term Assets, Total 2.303 1.613 0.746 0.812 0.265
    Total Current Liabilities 47.319 44.582 36.948 33.298 35.04
    Accounts Payable 15.525 15.367 13.14 11.537 11.711
    Accrued Expenses 17.77 16.245 10.118 9.489 8.866
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1.411 1.972 2.223 1.516 0.708
    Other Current Liabilities, Total 12.613 10.998 11.467 10.756 13.755
    Total Liabilities 88.363 86.041 79.43 58.066 65.492
    Total Long Term Debt 23.787 23.919 24.373 6.401 6.566
    Long Term Debt 23.692 23.793 24.207 6.188 6.313
    Capital Lease Obligations 0.095 0.126 0.166 0.213 0.253
    Other Liabilities, Total 16.994 17.29 17.72 17.218 18.998
    Total Equity 358.107 364.188 408.249 412.313 478.52
    Common Stock 0.043 0.043 0.043 0.043 0.042
    Additional Paid-In Capital 619.227 611.739 604.06 597.81 591.002
    Retained Earnings (Accumulated Deficit) -260.629 -246.915 -194.597 -184.64 -112.086
    Total Liabilities & Shareholders’ Equity 446.47 450.229 487.679 470.379 544.012
    Total Common Shares Outstanding 43.29 42.8322 42.706 42.5367 42.3311
    Total Preferred Shares Outstanding 0 0 0 0 0
    Deferred Income Tax 0.263 0.25 0.389 1.149 4.888
    Other Equity, Total -0.534 -0.679 -1.257 -0.9 -0.438
    Preferred Stock - Non Redeemable, Net 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -139.805 -8.908 1.983 -1.657 3.266
    Cash From Operating Activities -8.488 -4.593 6.645 1.213 2.348
    Cash From Operating Activities 6.775 4.663 2.035 0.718 0.338
    Non-Cash Items 134.988 13.835 3.988 7.086 2.064
    Changes in Working Capital -14.905 -2.258 -1.097 -4.472 -3.32
    Cash From Investing Activities -58.117 -13.192 -24.715 -27.018 -6.5
    Capital Expenditures -13.921 -14.756 -7.808 -2.33 -0.5
    Other Investing Cash Flow Items, Total -44.196 1.564 -16.907 -24.688 -6
    Cash From Financing Activities 16.316 -2.778 102.078 1.596 28.146
    Financing Cash Flow Items -1.843 -1.302 -0.499 0.415 15.707
    Issuance (Retirement) of Stock, Net 0.323 1.418 101.593 1.181 12.9
    Issuance (Retirement) of Debt, Net 17.836 -2.894 0.984 -0.025
    Net Change in Cash -50.397 -20.586 84.008 -24.209 23.994
    Total Cash Dividends Paid 0 -0.436
    Amortization 9.697 8.202 3.033 1.079
    Deferred Taxes -5.238 -20.127 -3.297 -1.541
    Foreign Exchange Effects -0.108 -0.023 0
    Cash Interest Paid 0.586 0.452
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -13.714 -139.805 -89.577 -79.62 -7.066
    Cash From Operating Activities -2.712 -8.488 -16.345 -17.841 -7.924
    Cash From Operating Activities 1.721 6.775 5.056 3.257 1.653
    Amortization 1.459 9.697 8.236 5.725 2.863
    Non-Cash Items 8.36 134.988 85.276 76.856 2.493
    Changes in Working Capital -0.551 -14.905 -20.399 -19.721 -7.268
    Cash From Investing Activities 2.926 -58.117 -43.223 -27.34 -2.27
    Capital Expenditures -4.296 -13.921 -8.206 -4.265 -2.27
    Other Investing Cash Flow Items, Total 7.222 -44.196 -35.017 -23.075 0
    Cash From Financing Activities -0.562 16.316 16.941 -0.47 -0.181
    Financing Cash Flow Items -0.56 -1.843 -1.246 -0.524 -0.313
    Issuance (Retirement) of Stock, Net 0.125 0.323 0.307 0.301 0.257
    Issuance (Retirement) of Debt, Net -0.127 17.836 17.88 -0.247 -0.125
    Net Change in Cash -0.337 -50.397 -42.803 -45.841 -10.397
    Deferred Taxes 0.013 -5.238 -4.937 -4.338 -0.599
    Foreign Exchange Effects 0.011 -0.108 -0.176 -0.19 -0.022
    Cash Interest Paid 0.497 0.586 0.23 0.121 0.091

    BioLife Solutions, Inc. Company profile

    About BioLife Solutions Inc

    BioLife Solutions, Inc. is engaged in developing, manufacturing, and marketing bioproduction tools and services to the cell and gene therapy (CGT) industry. Its products are used in basic and applied research, and commercial manufacturing of biologic-based therapies. The customers use its products to maintain the health and function of biologic material during sourcing, manufacturing, storage, and distribution of cells and tissues. It has a portfolio of tools and services that focus on biopreservation, frozen storage, and thawing of biologic materials. Its product offerings under bioproduction tools and services include Biopreservation media, Automated thawing devices, Cloud connected smart shipping containers, Freezer and storage technology and related components, and Biological and pharmaceutical material storage. Its Biopreservation media products consists of HypoThermosol FRS and CryoStor. Its Astero ThawSTAR product line includes automated vial and cryobag thawing products.

    Financial summary

    BRIEF: For the twelve months ended 31 December 2021, BioLife Solutions Inc revenues increased from $35.9M to $119.2M. Net loss decreased 57% to $8.4M. Revenues reflect Product revenue increase from $32.8M to $101.9M, Service revenue increase from $1.8M to $9.8M, Rental revenue increase from $1.4M to $7.4M. Lower net loss reflects Change in fair value of warrant liab. decrease of 99% to $121K (expense).

    Equity composition

    Common Stock $.001 Par, 02/11, 100M auth., 69,679,854 issd. Insiders control 70.67%. IPO 11/89, 1M units (5 Common + 5 Class A Warrants) at $5/unit by D.H. Blair & Co. Preferred Stock $.001 Par, 12,080 auth., 12,055 issd. 6/00, *9/02, Name changed from Cryomedical Sciences, Inc. 01/14, 1-for-14 Reverse stock split.

    Industry: Medical Equipment, Supplies & Distribution (NEC)

    Suite 310
    3303 Monte Villa Parkway
    BOTHELL
    WASHINGTON 98021
    US

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    BTC/USD

    26,623.50 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,595.79 Price
    +0.350% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    XRP/USD

    0.52 Price
    +0.780% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading